

AKIRIN2 Antibody (C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP17163b

Specification

AKIRIN2 Antibody (C-term) - Product Information

Application Primary Accession Other Accession

Reactivity Predicted Host Clonality Isotype Calculated MW Antigen Region WB,E <u>Q53H80</u> <u>Q25C79</u>, <u>B1AXD8</u>, <u>A8YXY8</u>, <u>NP_060534.1</u>, <u>A0A287BDC1</u> Human Bovine, Mouse, Pig, Rat Rabbit Polyclonal Rabbit IgG 22496 177-203

AKIRIN2 Antibody (C-term) - Additional Information

Gene ID 55122

Other Names Akirin-2, AKIRIN2, C6orf166

Target/Specificity

This AKIRIN2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 177-203 amino acids from the C-terminal region of human AKIRIN2.

- Dilution
- WB~~1:1000

E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions AKIRIN2 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

AKIRIN2 Antibody (C-term) - Protein Information

Name AKIRIN2 {ECO:0000303|PubMed:18066067, ECO:0000312|HGNC:HGNC:21407}



Function Molecular adapter that acts as a bridge between a variety of multiprotein complexes, and which is involved in embryonic development, immunity, myogenesis and brain development (PubMed:<u>34711951</u>). Plays a key role in nuclear protein degradation by promoting import of proteasomes into the nucleus: directly binds to fully assembled 20S proteasomes at one end and to nuclear import receptor IPO9 at the other end, bridging them together and mediating the import of pre-assembled proteasome complexes through the nuclear pore (PubMed:<u>34711951</u>). Involved in innate immunity by regulating the production of interleukin-6 (IL6) downstream of Toll-like receptor (TLR): acts by bridging the NF-kappa-B inhibitor NFKBIZ and the SWI/SNF complex, leading to promote induction of IL6 (By similarity). Also involved in adaptive immunity by promoting B-cell activation (By similarity). Involved in brain development: required for the survival and proliferation of cerebral cortical progenitor cells (By similarity). Involved in myogenesis: required for skeletal muscle formation and skeletal development, possibly by regulating interdigital tissue regression during limb development (By similarity).

Cellular Location

Nucleus. Cytoplasm {ECO:0000250|UniProtKB:B1AXD8} Membrane {ECO:0000250|UniProtKB:B1AXD8}. Note=Present mainly in the nuclear fraction, and at much lower level in the cytoplasmic and membrane fractions. {ECO:0000250|UniProtKB:B1AXD8}

Tissue Location

Widely expressed with the highest expression in peripheral blood leukocytes.

AKIRIN2 Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- <u>Dot Blot</u>
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

AKIRIN2 Antibody (C-term) - Images



AKIRIN2 Antibody (C-term) (Cat. #AP17163b) western blot analysis in U937 cell line lysates (35ug/lane).This demonstrates the AKIRIN2 antibody detected the AKIRIN2 protein (arrow).





Western blot analysis of AKIRIN2 (arrow) using rabbit polyclonal AKIRIN2 Antibody (C-term) (Cat. #AP17163b). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the AKIRIN2 gene.

AKIRIN2 Antibody (C-term) - Background

Required for the innate immune response. Downstream effector of the Toll-like receptor (TLR), TNF and IL-1 beta signaling pathways leading to the production of IL-6. Forms a complex with YWHAB that acts to repress transcription of DUSP1 (By similarity).

AKIRIN2 Antibody (C-term) - References

Komiya, Y., et al. J. Biol. Chem. 283(27):18753-18764(2008) Goto, A., et al. Nat. Immunol. 9(1):97-104(2008) Levy, D., et al. BMC Med. Genet. 8 SUPPL 1, S3 (2007) : Vasan, R.S., et al. BMC Med. Genet. 8 SUPPL 1, S2 (2007) : Olsen, J.V., et al. Cell 127(3):635-648(2006)